Ascentage Pharma Group International Announces Board Meeting for Annual Results and Dividend Consideration

Ascentage Pharma Group International has announced that a board meeting will be held on March 25, 2026. The primary purpose of this meeting is to consider and approve the company's annual results for the year ended December 31, 2025. Additionally, the board will discuss and, if deemed appropriate, declare a final dividend. The announcement was made on March 13, 2026, and is furnished as part of a Form 6-K filing with the U.S. Securities and Exchange Commission. The company, incorporated in the Cayman Islands, is listed on the Hong Kong Stock Exchange under the code 6855. The board composition includes executive, non-executive, and independent non-executive directors, with Dr. Yang Dajun serving as Chairman and Executive Director.